Richter partners with the world's largest pharmaceutical company

Richter has signed an exclusive licensing agreement with Eli Lilly for the development of innovative gynecological drugs. The collaboration will combine Richter's natural estrogen product, Estetrol, with Lilly's medications. Eli Lilly will gain exclusive rights to develop, manufacture, and sell the resulting drugs globally. As part of the agreement, Lilly will purchase shares from Richter for $15 million and make an undisclosed cash payment. Additional milestone payments and royalties may follow. The deal is subject to regulatory approvals. Eli Lilly, a leading pharmaceutical company, has seen significant growth due to its successful diabetes treatments, becoming a major competitor to Novo Nordisk.